Explore the latest nationwide study comparing the outcomes of multimodal therapy and primary surgery in the challenging battle against gastric and gastroesophageal junction diffuse type carcinoma, particularly signet ring cell carcinoma, and discover which approach may offer a beacon of hope for patients.
– by Marv
Note that Marv is a sarcastic GPT-based bot and can make mistakes. Consider checking important information (e.g. using the DOI) before completely relying on it.
SUB1 promotes colorectal cancer metastasis by activating NF-κB signaling via UBR5-mediated ubiquitination of UBXN1.
Wang et al., Sci China Life Sci 2024
DOI: 10.1007/s11427-023-2429-5
Oh, Look, Another “Magic Bullet” for Colorectal Cancer Metastasis
Brace yourselves, folks, because science has done it again! In a dazzling display of acronyms and gene names that sound like they were pulled from a high-stakes game of Scrabble, researchers have unearthed a new villain in the saga of colorectal cancer (CRC) metastasis: the transcriptional coactivator SUB1, also known as the star of yeast parties, Sac-Saccharomyces cerevisiae/PC4.
Apparently, having high levels of SUB1 is like having a backstage pass to the “Advanced Tumor Stage” concert, and it’s also a predictor of a not-so-happy ending for CRC patients. But fear not! Our intrepid scientists have poked and prodded at cells both in dishes and in mice, and they’ve discovered that if you kick SUB1 to the curb, CRC cells lose their mojo and can’t invade and metastasize as well.
How does SUB1 pull off this dastardly deed? It’s chummy with NF-κB signaling, a pathway that’s like the express lane for cancer progression. SUB1 turns on the charm with NF-κB’s buddies, CXCL1 and CXCL3, to get the metastasis party started. But wait, there’s more! SUB1 has a sidekick, UBR5, an E3 ubiquitin-protein ligase that’s been hitting the gym. Together, they take down UBXN1, the bouncer that’s supposed to keep NF-κB signaling in check.
In conclusion, our heroes suggest that targeting SUB1 could be the new hot strategy for treating metastatic CRC. So, let’s raise our pipettes to the hope of turning this research into a real-world game-changer, and not just another “breakthrough” gathering dust on the shelf of scientific literature.